<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543605</url>
  </required_header>
  <id_info>
    <org_study_id>PROA-SENIOR (PRO-FIS-2017-01)</org_study_id>
    <nct_id>NCT03543605</nct_id>
  </id_info>
  <brief_title>Clinical/Microbiological Impact of a Specific Antimicrobial Stewardship Program for Nursing Homes</brief_title>
  <acronym>PROA-SENIOR</acronym>
  <official_title>Impacto clínico y microbiológico de un Programa de optimización de Antimicrobianos específico Para Centros Socio-sanitarios. Ensayo clínico Aleatorizado Por Grupos. Ensayo PROA-SENIOR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: In nursing homes, excessive and inappropriate use of antimicrobials, adverse
      events caused by these drugs, and infections by multidrug-resistant bacteria (MDRB) are more
      frequent than in the general population, posing a serious Public Health risk. Antimicrobial
      stewardship programs (ASP) are a key strategy to improve the use of antibiotics and to fight
      against bacterial resistance. Its usefulness in hospitals has been demonstrated. The Centers
      for Disease Control and Prevention urge the implementation ASP in nursing homes, with
      measures taken from the ASP in hospitals, but the available information is so limited that it
      does not allow specific recommendations to be made for these centers.

      Objectives: To know if an ASP with an individual intervention measure, the clinical
      assessments, is better to an ASP with general intervention measures, both designed
      specifically for nursing homes, and what is the clinical and ecological impact of both, on
      the baseline situation.

      Methods: a) Randomized clinical trial, in parallel groups, for comparison of both ASP. b)
      Quasi-Experimental study of timeseries for the evaluation of the clinical and ecological
      impact on the baseline situation. The following indicators will be analyzed: the use of
      antimicrobials in the centers; the intestinal microbiota diversity of nursing home residents,
      and the incidence of MDRB and Clostridium difficile infections; and the frequency of adverse
      events caused by antimicrobials and hospital admissions for infections. The study population
      will be 2.220 residents from 20 public nursing homes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The study will be masked in the first year (pre-intervention) and open in the year of intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Total antimicrobial pressure</measure>
    <time_frame>From date of randomization, assessed monthly up to 12 months</time_frame>
    <description>Change from baseline of antimicrobial pressure, which will be measured using the recommended international standard, the defined daily dose (DDD) / 1000 residents / day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antimicrobials adverse events</measure>
    <time_frame>From date of randomization, assessed monthly up to 12 months</time_frame>
    <description>The frequency of side effects of the antimicrobials that require admission will be evaluated by measuring the number of hospital admissions due to adverse effects of antimicrobials / 1000 residents / day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections by multiresistant bacteria</measure>
    <time_frame>From date of randomization, assessed monthly up to 12 months</time_frame>
    <description>Incidence density (number of isolates in clinical samples / 1000 residents / day) of the following pathogens: quinolone resistant E.coli; E. coli BLEE, Klebsiella pneumoniae BLEE, carbapenemase-producing enterobacteria, methicillin-resistant Staphylococcus aureus (MRSA), in samples sent for culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections of C. difficile</measure>
    <time_frame>From date of randomization, assessed monthly up to 12 months</time_frame>
    <description>Incidence density (number of C. difficile isolates in clinical samples / 1000 residents / day) sent for toxin detection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2220</enrollment>
  <condition>Human Microbiome</condition>
  <condition>Antibiotic Resistant Infection</condition>
  <condition>Nursing Homes</condition>
  <arm_group>
    <arm_group_label>PROA Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It consists of the intervention measures described in the general antimicrobial stewardship program (PROA Control) plus clinical advice.
The clinical assessments have been adapted for this project to the unique characteristics of infectious diseases in nursing homes.
These are individual training activities whose main objective is to modify prescribing behaviors when they are inadequate and reinforce them when they are correct.
They are carried out between the medical adviser, an expert in infectious diseases, and the doctor of the nursing home, through the structured review of a case attended by the doctor in the last 24 hours. The recommendations are not compulsory, and do not seek to change the decisions made in that patient, but the future ones in the case that is necessary.
The counseling will be done by video-conference, with an approximate duration of 10 minutes. Each of the doctors will receive two monthly assessments during the intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROA Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention of the general antimicrobial stewardship program (PROA) contains the following set of measures:
Creation of the local team of the PROA: one of the Family Physicians responsible for the patients and the pharmacist of the reference hospital of the center.
Presentation of the project by the local team in its own center.
Choice of the Aljarafe guide as a reference document for the diagnosis and treatment of infectious diseases. It is an accredited guide and widely disseminated among primary care and hospital doctors.
Permanent information of the project (poster with its synthesis, a pocket triptych with the guide for the clinical management of the main clinical syndromes of infections in the residents of the nursing homes).
Feedback of the results that will serve each center to know the evolution of its results, and to stimulate the comparison with the other centers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PROA Experimental</intervention_name>
    <description>PROA Control plus clinical advice</description>
    <arm_group_label>PROA Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PROA Control</intervention_name>
    <description>PROA Control</description>
    <arm_group_label>PROA Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Public nursing homes under the ownership of the Department of Equality and Social
             Policies of the Junta de Andalucía

        Exclusion Criteria:

          -  Nursing homes that are not under the ownership of the Department of Equality and
             Social Policies of the Junta de Andalucía
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Miguel Cisneros Herreros, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virgen del Rocío University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara Rosso Fernández, PhD, MD</last_name>
    <phone>0034 955012144</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virgen del Rocío University Hospital</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Clara Rosso Fernández, MD, PhD</last_name>
      <phone>0034 955 01 21 44</phone>
      <email>claram.rosso.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>José Miguel Cisneros Herreros, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Aranzazu Irastorza Aldasoro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Serrano Martino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Antonio Lepe Jiménez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Antonio Expósito Tirado</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Jiménez-Jorge, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eloy González Barbero</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rocío Fernández Urrusuno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Fernández Del Valle</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Molina Gil-Bermejo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco José Guerrero García</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Victoria Gil Navarro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gema Labrador Herrera</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joaquín Torres Moreno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucía Carmen Carrión Domínguez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Germán Peñalva Moreno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Inmaculada Vázquez Cruz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yolanda Santaella Guardiola</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

